<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">

	<form>

		<distribution-code display="yes">II</distribution-code>

		<congress>109th CONGRESS</congress>

		<session>1st Session</session>

		<legis-num>S. 1128</legis-num>

		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>

		<action>

			<action-date date="20050526">May 26, 2005</action-date>

			<action-desc><sponsor name-id="S247">Mr. Wyden</sponsor> (for himself

			 and <cosponsor name-id="S296">Mr. Sununu</cosponsor>) introduced the following

			 bill; which was read twice and referred to the

			 <committee-name committee-id="SSFI00">Committee on

			 Finance</committee-name></action-desc>

		</action>

		<legis-type>A BILL</legis-type>

		<official-title>To amend title XIX of the Social Security Act to provide

		  for increased rebates under the medicaid program for prescription drugs that

		  are directly advertised to consumers, to require other Federal programs

		  purchasing or reimbursing for such drugs to establish payment and reimbursement

		  mechanisms that reduce the costs of those drugs, and for other

		  purposes.</official-title>

	</form>

	<legis-body>

		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short

			 title</header><text display-inline="no-display-inline">This Act may be cited as

			 the <quote><short-title>Pharmaceutical Advertising and

			 Prudent Purchasing Act</short-title></quote>.</text>

		</section><section id="id89E3D38F99D64F68A71FFDA90FB7F2EE"><enum>2.</enum><header>Increased

			 rebates under the medicaid program for prescription drugs directly advertised

			 to consumers</header>

			<subsection id="idD791B92B52C24A6C9DB44050A1EEC2C1"><enum>(a)</enum><header>In

			 general</header><text>Section 1927(b) of the Social Security Act (42 U.S.C.

			 1396r–8(b)) is amended by adding at the end the following:</text>

				<quoted-block display-inline="no-display-inline" id="id08755AA7B0FB45C5A0698E79306E08FF" style="OLC">

					<paragraph id="id4EC7A4E824654F2697E34D9A4EFCF939"><enum>(5)</enum><header>Increase in

				amount of rebate for covered outpatient drugs directly advertised to

				consumers</header>

						<subparagraph id="id06A847A02DF245CCB1865E0315555DFF"><enum>(A)</enum><header>In

				general</header><text>A rebate agreement under this subsection shall provide

				for an increase in the amount of the rebate determined under subsection (c)

				with respect to each covered outpatient drug of a manufacturer for which

				payment is made under the State program under this title if the manufacturer of

				such drug fails to certify to the Secretary that the drug was not directly

				advertised to consumers during the rebate period applicable to such

				agreement.</text>

						</subparagraph><subparagraph id="id6C060DB6283845F7B7E59B47F06A4304"><enum>(B)</enum><header>Adjustment of

				rebate formula</header>

							<clause id="idBA15EA82CD3B4E7EA34787ED54274302"><enum>(i)</enum><header>In

				general</header><text>Not later than 180 days after the date of enactment of

				this paragraph, the Secretary shall determine appropriate adjustments to make

				to the formula used to calculate the amount of a rebate under subsection (c) to

				determine the increased amount of the rebate required under subparagraph (A),

				including, to the extent the Secretary determines appropriate, to the

				application of the average manufacturer price and best price in such

				formula.</text>

							</clause><clause id="id54DCD737DDDB4795B25902EFDB8022B7"><enum>(ii)</enum><header>Requirements</header><text>In

				determining the adjustments required under clause (i), the Secretary

				shall—</text>

								<subclause id="id57C89CE7F52C49C1BFDFC658A4843B96"><enum>(I)</enum><text>take into account

				the increased costs to the State program established under this title resulting

				from the purchase of covered outpatient drugs that are directly advertised to

				consumers; and</text>

								</subclause><subclause id="id515C7E8E98EA459BB639B4E35BB4FDB5"><enum>(II)</enum><text>consult with

				manufacturers.</text>

								</subclause></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7AC70BDC8F6C43449899BA6DB72C72E0"><enum>(C)</enum><header>Definition of

				directly advertised to consumers</header><text>In this section, the term

				<term>directly advertised to consumers</term> means a reminder ad or product

				claim regarding a covered outpatient drug that is disseminated through radio,

				television, or other electronic media, print media, or outdoor

				advertising.</text>

						</subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>

			</subsection><subsection id="id657752FAA93B4358A1BBA74B2B6A2A38"><enum>(b)</enum><header>Effective

			 date</header><text>The amendment made by this section applies to rebate

			 agreements entered into or renewed under section 1927 of the Social Security

			 Act (42 U.S.C. 1396r–8) on or after the date that is 180 days after the date of

			 enactment of this Act.</text>

			</subsection></section><section id="idCE201C74DE644072A69BD99A87894322"><enum>3.</enum><header>Reduced payment

			 and reimbursement mechanisms for other federal programs that purchase or

			 provide reimbursement for prescription drugs that are directly advertised to

			 consumers</header>

			<subsection id="id7A575EAFA647410387D29DADF49E422D"><enum>(a)</enum><header>In

			 general</header><text>Not later than 180 days after the date of enactment of

			 this Act, the Secretary of Health and Human Services and the Secretary of

			 Veterans Affairs each shall develop and implement procedures under which any

			 master agreement, pricing agreement, or contract entered into on or after that

			 date for the procurement or purchase of a covered drug or a covered outpatient

			 drug by a Federal agency or reimbursement program described in subsection (b)

			 shall provide that the agency or program shall pay a negotiated reduced price

			 for such drug unless the manufacturer has certified to the head of the agency

			 or program that the drug was not directly advertised to consumers during the

			 12-month period preceding the date of such procurement or purchase.</text>

			</subsection><subsection id="id4C6F88E3BCC343A097785740E1D239D5"><enum>(b)</enum><header>Federal

			 agencies and programs described</header><text>For purposes of subsection (a),

			 the Federal agencies and reimbursement programs described in this subsection

			 are the following:</text>

				<paragraph id="id36A3304606FE4AA39AD5CE115DE51E18"><enum>(1)</enum><text>The Public Health

			 Service, including health-related programs administered by the Indian Health

			 Service, and health-related programs funded under the Public Health Service

			 Act, including the drug pricing agreement program established under section

			 340B of such Act (42 U.S.C. 256b).</text>

				</paragraph><paragraph id="idF498D8AE9CDC4C5CB9FA474196C36AF7"><enum>(2)</enum><text>The Department of

			 Veterans Affairs and the program of medical care furnished by the Secretary of

			 Veterans Affairs.</text>

				</paragraph><paragraph id="id72274D88D6A248AEAB0EFA987527D42C"><enum>(3)</enum><text>The Department of

			 Defense and the Defense Health Program.</text>

				</paragraph></subsection><subsection id="idF90988260C7F43679C9BA25AE3C58878"><enum>(c)</enum><header>Definitions</header><text>In

			 this section:</text>

				<paragraph id="idE1F5BCEBC7384478A4EB510C2C9DA41C"><enum>(1)</enum><header>Covered

			 drug</header><text>The term <term>covered drug</term> has the meaning given

			 that term in section 8126(h)(2) of title 38, United States Code.</text>

				</paragraph><paragraph id="id78BFF440B1A24E5790316DE004CB8EFA"><enum>(2)</enum><header>Covered

			 outpatient drug</header><text>The term <term>covered outpatient drug</term> has

			 the meaning given that term in section 1927(k)(2) of the Social Security Act

			 (42 U.S.C. 1396r–8(k)(2)).</text>

				</paragraph><paragraph id="idD551DFC1E485425C99916C1C0A58C75B"><enum>(3)</enum><header>Directly

			 advertised to consumers</header><text>The term <term>directly advertised to

			 consumers</term> means a reminder ad or product claim regarding a covered drug

			 or a covered outpatient drug that is disseminated through radio, television, or

			 other electronic media, print media, or outdoor advertising.</text>

				</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id39B1B82D98944D59A827D337B265E7BB"><enum>(4)</enum><header>Manufacturer</header><text>The

			 term <term>manufacturer</term> has the meaning given that term in section

			 8126(h)(4) of title 38, United States Code, and section 1927(k)(5) of the

			 Social Security Act (42 U.S.C. 1936r–8(k)(5)).</text>

				</paragraph></subsection><subsection id="id1137D8E3759349C8B05ED94CFD36A180"><enum>(d)</enum><header>Conforming

			 amendments</header>

				<paragraph id="id5E5B52C2505D4FEBA0CAA81BE9D0713F"><enum>(1)</enum><header>Prescription

			 drugs purchased by covered entities under agreements entered into under the

			 public health service act</header><text>Section 340B(a) of the Public Health

			 Service Act (42 U.S.C. 256b(a)) is amended—</text>

					<subparagraph id="id160BC37F0CB3423DB018231CA711BE56"><enum>(A)</enum><text>in paragraph (1),

			 by inserting <quote>or required under paragraph (11)</quote> after <quote>as

			 provided by the Secretary</quote>; and</text>

					</subparagraph><subparagraph id="id1E8523AE43A54FEE828116A2E44E775D"><enum>(B)</enum><text>by adding at the

			 end the following:</text>

						<quoted-block display-inline="no-display-inline" id="idA65276DD0F5444D99E28B3F1FA951658" style="OLC">

							<paragraph commented="no" display-inline="no-display-inline" id="id954E64D62B0E4FF193A5A20F1EBD3EF0"><enum>(11)</enum><header>Reduced

				negotiated price for covered drugs advertised directly to consumers</header>

								<subparagraph commented="no" display-inline="no-display-inline" id="id451D07435027449BB072F1E0B97DDE06"><enum>(A)</enum><header>In

				general</header><text>An agreement entered into under paragraph (1) shall

				provide that with respect to each covered drug of the manufacturer that is

				purchased by a covered entity, the price charged shall not exceed the reduced

				negotiated price for that drug in accordance with the procedures established

				under section 3(a) of the <short-title>Pharmaceutical

				Advertising and Prudent Purchasing Act</short-title> if the manufacturer fails

				to certify to the Secretary that the drug was not directly advertised to

				consumers during the 12-month period preceding the date of such

				purchase.</text>

								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id07E5574C742C4B25952095A47372A04B"><enum>(B)</enum><header>Definition of

				directly advertised to consumers</header><text display-inline="yes-display-inline">In subparagraph (A), the term

				<term>directly advertised to consumers</term> means a reminder ad or product

				claim regarding a covered outpatient drug that is disseminated through radio,

				television, or other electronic media, print media, or outdoor

				advertising.</text>

								</subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>

					</subparagraph></paragraph><paragraph id="idE5552F98769F4AFAB7C0D540E630762B"><enum>(2)</enum><header>Procurement of

			 prescription drugs by the department of veterans affairs, department of

			 defense, the public health service (including the indian health service) and

			 the coast guard</header><text>Section 8126 of title 38, United States Code, is

			 amended—</text>

					<subparagraph id="idAEAE2220F3C14FAE89EBC4694D546296"><enum>(A)</enum><text>in subsection

			 (a)—</text>

						<clause id="id7C2B75FF71C94E24911CFB834DEB660D"><enum>(i)</enum><text>in

			 paragraph (3), by striking <quote>and</quote> at the end;</text>

						</clause><clause id="id138CFE74C031437D9356ABAFD39A5188"><enum>(ii)</enum><text>by

			 redesignating paragraph (4) as paragraph (5);</text>

						</clause><clause id="idA41C3A6D81B9472B8BE50A6385F2E866"><enum>(iii)</enum><text>in paragraph

			 (5) (as redesignated by clause (ii)), by striking <quote>and (3)</quote> and

			 inserting <quote>(3), and (4)</quote>; and</text>

						</clause><clause id="idCD1373D2C0E742CF8C13C5C0DFDB8C2E"><enum>(iv)</enum><text>by

			 inserting after paragraph (3), the following:</text>

							<quoted-block display-inline="no-display-inline" id="id4C7897B06AB64D04A79D516A6965D719" style="OLC">

								<paragraph commented="no" display-inline="no-display-inline" id="id67B14FBF3E3A4A0C8858CE44C92C69BA"><enum>(4)</enum><text>with respect to

				each covered drug of the manufacturer that is procured by a Federal agency

				described in subsection (b) under depot contracting systems, a national

				contract entered into by the Secretary, or under the Federal Supply Schedule,

				the price charged shall not exceed the reduced negotiated price for that drug

				in accordance with the procedures established under section 3(a) of the

				<short-title>Pharmaceutical Advertising and Prudent

				Purchasing Act</short-title> if the manufacturer fails to certify to the

				Secretary or the head of the Federal agency involved that the drug was not

				directly advertised to consumers during the 12-month period preceding the date

				of such procurement;</text>

								</paragraph><after-quoted-block>;

				and</after-quoted-block></quoted-block>

						</clause></subparagraph><subparagraph id="id5D15038076024751B565999C0D9D9174"><enum>(B)</enum><text>in subsection

			 (h), by adding at the end the following:</text>

						<quoted-block display-inline="no-display-inline" id="id9DF41679706F4B2882B2418A8CEB8E1C" style="OLC">

							<paragraph id="id053737D1649948CEA706B0955021CD4C"><enum>(7)</enum><header>Directly

				advertised to consumers</header><text>The term <term>directly advertised to

				consumers</term> means a reminder ad or product claim regarding a covered drug

				that is disseminated through radio, television, or other electronic media,

				print media, or outdoor

				advertising.</text>

							</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>

					</subparagraph></paragraph></subsection><subsection id="id964ECB9FD3BC421BBBABB79273C47847"><enum>(e)</enum><header>Effective

			 date</header><text>The amendments made by this section apply to master

			 agreements, pricing agreements, and contracts entered into or renewed on or

			 after the date that is 180 days after the date of enactment of this Act.</text>

			</subsection></section><section id="id03C28D7CBB444AD1840000EC36E48F61"><enum>4.</enum><header>Report to

			 congress on strategies to reduce the cost of prescription drugs covered under

			 medicare and other federal programs that are directly advertised to

			 consumers</header>

			<subsection id="id743F946A217A47179DF666096536461E"><enum>(a)</enum><header>In

			 general</header><text>Not later than January 1, 2007, the Secretary of Health

			 and Human Services, in consultation with the Secretary of Veterans Affairs,

			 shall submit a report to Congress that contains the following

			 information:</text>

				<paragraph id="ID65a7706dfe05473981eec32f9a2e493d"><enum>(1)</enum><text>The percentage of

			 costs for prescription drugs that are directly advertised to consumers that are

			 passed on to Federal agencies and programs that purchase or provide

			 reimbursement for such drugs.</text>

				</paragraph><paragraph id="ID1e862ebddcef49d9b31cb272c50998a2"><enum>(2)</enum><text>The 25 most

			 frequently prescribed drugs that are directly advertised to consumers and are

			 purchased or reimbursed by Federal agencies and programs.</text>

				</paragraph><paragraph id="id61E24D7EC8AC4EA29CE753210AFBDF2B"><enum>(3)</enum><text>The 25 most

			 costly prescription drugs that are directly advertised to consumers and are

			 purchased or reimbursed by Federal agencies and programs.</text>

				</paragraph><paragraph id="ID2f9339fb3aa147d9903c1d1cca22a19f"><enum>(4)</enum><text>The aggregate

			 amount spent by manufacturers of prescription drugs—</text>

					<subparagraph id="idDB5C45480BCC43E78992593E023943D7"><enum>(A)</enum><text>to directly

			 advertise to consumers; and</text>

					</subparagraph><subparagraph id="idD0A6F191112A4BF388B068324849D383"><enum>(B)</enum><text>for the 25 most

			 costly prescription drugs that are directly advertised to consumers.</text>

					</subparagraph></paragraph><paragraph id="ID85482c8e109246a3a25c1c840ea66de1"><enum>(5)</enum><text>Mechanisms for

			 Federal agencies and programs to share information concerning—</text>

					<subparagraph id="idC75649A7F28345B99968B949A9F10E91"><enum>(A)</enum><text>which

			 prescription drugs are directly advertised to consumers;</text>

					</subparagraph><subparagraph id="id1E6AFEE2009F4FD9B516D27F9AA44DCD"><enum>(B)</enum><text>the costs to

			 Federal agencies and programs of such drugs; and</text>

					</subparagraph><subparagraph id="id0BE13B8353E146809E0C36F0EC9F8582"><enum>(C)</enum><text>utilization,

			 cost, and reimbursement data regarding the purchase of such drugs, separately

			 identified with respect to the medicare program and other Federal agencies and

			 programs, and disaggregated for age cohorts, gender, and diagnoses of the

			 individuals using such drugs.</text>

					</subparagraph></paragraph><paragraph id="ID4919a970b17844b48eecfd660ccd9adf"><enum>(6)</enum><text>Recommendations

			 for legislative or administrative changes or alternative strategies, separately

			 identified with respect to the medicare program and other Federal agencies and

			 programs, to ensure that Federal payments for prescription drugs are reduced

			 for prescription drugs directly advertised to consumers.</text>

				</paragraph><paragraph id="IDdedb06ab11154f029968ddd56d79591f"><enum>(7)</enum><text>Strategies to

			 ensure that prescription drug utilization under Federal agencies and programs

			 is based on health needs.</text>

				</paragraph><paragraph id="idF791CCB747854C8B809F062D19BD0641"><enum>(8)</enum><text>Such other

			 recommendations for legislation or administrative action as the Secretary

			 determines to be appropriate.</text>

				</paragraph></subsection><subsection id="id5A096E0ED1664CFC88EEC9EBCB2C6BD3"><enum>(b)</enum><header>Definitions</header><text>In

			 this section:</text>

				<paragraph id="id4F4300613FF24EFB93B9CDCE7AD0166A"><enum>(1)</enum><header>Directly

			 advertised to consumers</header><text>The term <term>directly advertised to

			 consumers</term> has the meaning given that term in section 1927(b)(5)(C) of

			 the Social Security Act (as added by section 2(a)).</text>

				</paragraph><paragraph id="id447B6981EA744520BA5EF6B71E3496BC"><enum>(2)</enum><header>Federal agency

			 and program</header><text>The term <term>Federal agency and program</term>

			 means the Federal agencies and programs described in section 3(b) and includes

			 the medicare program established under title XVIII of the Social Security Act

			 (42 U.S.C. 1395 et seq.).</text>

				</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id6A9A9D4BE77242FD85136117FD818AA3"><enum>(3)</enum><header>Manufacturer</header><text display-inline="yes-display-inline">The term <term>manufacturer</term> has the

			 meaning given that term in section 8126(h)(4) of title 38, United States Code,

			 and section 1927(k)(5) of the Social Security Act (42 U.S.C.

			 1396r–8(k)(5)).</text>

				</paragraph></subsection></section></legis-body>

</bill>

